Evidence map›Paper›PMID 30834549›Full record

ArticleBritish journal of clinical pharmacology2019

Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Jasmini Alagaratnam, Sujan Dilly-Penchala, Elizabeth Challenger, Laura Else, Ken Legg, Claire Petersen, Brynmor Jones, Ranjababu Kulasegaram, Star Seyedkazemi, Eric Lefebvre and 2 more

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jasmini AlagaratnamDivision of Infectious Diseases, Department of Medicine, Imperial College London, London, UK.ORCID 0000-0003-2256-423X
Sujan Dilly-PenchalaDepartment of Pharmacology, University of Liverpool, Liverpool, UK.
Elizabeth ChallengerDepartment of Pharmacology, University of Liverpool, Liverpool, UK.
Laura ElseDepartment of Pharmacology, University of Liverpool, Liverpool, UK.
Ken LeggDivision of Infectious Diseases, Department of Medicine, Imperial College London, London, UK.
Claire PetersenDivision of Infectious Diseases, Department of Medicine, Imperial College London, London, UK.
Brynmor JonesDepartment of HIV & Genitourinary Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
Ranjababu KulasegaramDepartment of HIV & Genitourinary Medicine, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Star SeyedkazemiClinical Development, Allergan plc, South San Francisco, California.
Eric LefebvreClinical Development, Allergan plc, South San Francisco, California.
Saye KhooDepartment of Pharmacology, University of Liverpool, Liverpool, UK.
Alan WinstonDivision of Infectious Diseases, Department of Medicine, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-HIV AgentsCCR5 Receptor AntagonistsCognitionCognitive DysfunctionHIV-1HIV InfectionsHumansImidazolesRNA, ViralSulfoxidesAnti-HIV AgentsCCR5 Receptor AntagonistscenicrivirocImidazolesRNA, ViralSulfoxides

Identifiers

PMID30834549
PMCPMC6475690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.